{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:14:25Z","timestamp":1793661265606,"version":"4.5.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009941","name":"Ministry of Defence","doi-asserted-by":"publisher","award":["ArmyHQ2\/00269"],"award-info":[{"award-number":["ArmyHQ2\/00269"]}],"id":[{"id":"10.13039\/100009941","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Stress fractures are a common and potentially debilitating overuse injury to bone and occur frequently among military recruits and athletes. Recovery from a lower body stress fracture typically requires several weeks of physical rehabilitation. Teriparatide, a recombinant form of the bioactive portion of parathyroid hormone (1\u201334 amino acids), is used to treat osteoporosis, prevent osteoporotic fractures, and enhance fracture healing due to its net anabolic effect on bone. The study aim is to investigate the effect of teriparatide on stress fracture healing in young, otherwise healthy adults undergoing military training.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In a two-arm, parallel, prospective, randomised controlled, intention-to-treat trial, Army recruits (<jats:italic>n<\/jats:italic> = 136 men and women, 18\u201340\u2009years) with a magnetic resonance imaging (MRI) diagnosed lower body stress fracture (pelvic girdle, sacrum, coccyx, or lower limb) will be randomised to receive either usual Army standard care, or teriparatide and usual Army standard care. Teriparatide will be self-administered by subcutaneous injections (20\u2009\u03bcg\/day) for 16\u2009weeks, continuing to 24\u2009weeks where a fracture remains unhealed at week 16. The primary outcome will be the improvement in radiological healing by two grades or more, or reduction to grade zero, 8\u2009weeks after randomisation, assessed using Fredericson grading of MRI by radiologists blind to the randomisation. Secondary outcomes will be time to radiological healing, assessed by MRI at 8, 10, 12, 14, 16, 20 and 24\u2009weeks, until healed; time to clinical healing, assessed using a clinical severity score of injury signs and symptoms; time to discharge from Army physical rehabilitation; pain, assessed by visual analogue scale; health-related quality of life, using the Short Form (36) Health Survey; and adverse events. Exploratory outcomes will include blood and urine biochemistry; bone density and morphology assessed using dual-energy X-ray absorptiometry, peripheral quantitative computed tomography (pQCT), and high-resolution pQCT; physical activity measured using accelerometers; and long-term future fracture rate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study will evaluate whether teriparatide, in addition to standard care, is more effective for stress fracture healing than standard care alone in Army recruits who have sustained a lower body stress fracture.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04196855\">NCT04196855<\/jats:ext-link>. Registered on 12 December 2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05556-3","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T12:02:54Z","timestamp":1630324974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Teriparatide and stress fracture healing in young adults (RETURN \u2013 Research on Efficacy of Teriparatide Use in the Return of recruits to Normal duty): study protocol for a randomised controlled trial"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7922-5549","authenticated-orcid":false,"given":"Alexander T.","family":"Carswell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine G.","family":"Eastman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Shepstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Payerne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andoni P.","family":"Toms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"MacKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Swart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie P.","family":"Greeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"issue":"1","key":"5556_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.csm.2005.08.005","volume":"25","author":"RA Snyder","year":"2006","unstructured":"Snyder RA, Koester MC, Dunn WR. Epidemiology of stress fractures. Clin Sports Med. 2006;25(1):37\u201352, viii. https:\/\/doi.org\/10.1016\/j.csm.2005.08.005.","journal-title":"Clin Sports Med."},{"issue":"1","key":"5556_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12891-015-0558-6","volume":"16","author":"J Sharma","year":"2015","unstructured":"Sharma J, Greeves JP, Byers M, Bennett AN, Spears IR. Musculoskeletal injuries in British Army recruits: a prospective study of diagnosis-specific incidence and rehabilitation times. BMC Musculoskelet Disord. 2015;16(1):106. https:\/\/doi.org\/10.1186\/s12891-015-0558-6.","journal-title":"BMC Musculoskelet Disord."},{"issue":"5","key":"5556_CR3","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1302\/0301-620X.67B5.4055871","volume":"67","author":"C Milgrom","year":"1985","unstructured":"Milgrom C, Giladi M, Stein M, Kashtan H, Margulies JY, Chisin R, et al. Stress fractures in military recruits. A prospective study showing an unusually high incidence. J Bone Joint Surg Br. 1985;67(5):732\u20135.","journal-title":"J Bone Joint Surg Br."},{"issue":"4","key":"5556_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.7205\/MILMED-D-10-00322","volume":"176","author":"L Wentz","year":"2011","unstructured":"Wentz L, Liu PY, Haymes E, Ilich JZ. Females have a greater incidence of stress fractures than males in both military and athletic populations: a systemic review. Mil Med. 2011;176(4):420\u201330. https:\/\/doi.org\/10.7205\/MILMED-D-10-00322.","journal-title":"Mil Med."},{"issue":"3","key":"5556_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11914-996-0029-y","volume":"4","author":"SJ Warden","year":"2006","unstructured":"Warden SJ, Burr DB, Brukner PD. Stress fractures: pathophysiology, epidemiology, and risk factors. Curr Osteoporos Rep. 2006;4(3):103\u20139. https:\/\/doi.org\/10.1007\/s11914-996-0029-y.","journal-title":"Curr Osteoporos Rep."},{"key":"5556_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/OAJSM.S39512","volume":"6","author":"L Kahanov","year":"2015","unstructured":"Kahanov L, Eberman LE, Games KE, Wasik M. Diagnosis, treatment, and rehabilitation of stress fractures in the lower extremity in runners. Open Access J Sports Med. 2015;6:87\u201395. https:\/\/doi.org\/10.2147\/OAJSM.S39512.","journal-title":"Open Access J Sports Med."},{"issue":"3","key":"5556_CR7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1210\/jcem.77.3.8370698","volume":"77","author":"ML Hetland","year":"1993","unstructured":"Hetland ML, Haarbo J, Christiansen C. Low bone mass and high bone turnover in male long distance runners. J Clin Endocrinol Metab. 1993;77(3):770\u20135. https:\/\/doi.org\/10.1210\/jcem.77.3.8370698.","journal-title":"J Clin Endocrinol Metab."},{"issue":"apr24 3","key":"5556_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e2511","volume":"344","author":"J Pegrum","year":"2012","unstructured":"Pegrum J, Crisp T, Padhiar N. Diagnosis and management of bone stress injuries of the lower limb in athletes. BMJ. 2012;344(apr24 3):e2511. https:\/\/doi.org\/10.1136\/bmj.e2511.","journal-title":"BMJ."},{"issue":"10","key":"5556_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00402-003-0579-8","volume":"123","author":"CH Lee","year":"2003","unstructured":"Lee CH, Huang GS, Chao KH, Jean JL, Wu SS. Surgical treatment of displaced stress fractures of the femoral neck in military recruits: a report of 42 cases. Arch Orthop Trauma Surg. 2003;123(10):527\u201333. https:\/\/doi.org\/10.1007\/s00402-003-0579-8.","journal-title":"Arch Orthop Trauma Surg."},{"issue":"1","key":"5556_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1517\/14712598.2015.977249","volume":"15","author":"EJ Campbell","year":"2015","unstructured":"Campbell EJ, Campbell GM, Hanley DA. The effect of parathyroid hormone and teriparatide on fracture healing. Expert Opin Biol Ther. 2015;15(1):119\u201329. https:\/\/doi.org\/10.1517\/14712598.2015.977249.","journal-title":"Expert Opin Biol Ther."},{"key":"5556_CR11","first-page":"6040379","volume":"2016","author":"S Lou","year":"2016","unstructured":"Lou S, Lv H, Wang G, Zhang L, Li M, Li Z, et al. The effect of teriparatide on fracture healing of osteoporotic patients: a meta-analysis of randomized controlled trials. Biomed Res Int. 2016;2016:6040379.","journal-title":"Biomed Res Int."},{"issue":"1","key":"5556_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.11005\/jbm.2017.24.1.65","volume":"24","author":"SM Kim","year":"2017","unstructured":"Kim SM, Kang KC, Kim JW, Lim SJ, Hahn MH. Current role and application of teriparatide in fracture healing of osteoporotic patients: a systematic review. J Bone Metab. 2017;24(1):65\u201373. https:\/\/doi.org\/10.11005\/jbm.2017.24.1.65.","journal-title":"J Bone Metab."},{"issue":"3","key":"5556_CR13","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1210\/endo-112-3-1000","volume":"112","author":"R Podbesek","year":"1983","unstructured":"Podbesek R, Edouard C, Meunier PJ, Parsons JA, Reeve J, Stevenson RW, et al. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology. 1983;112(3):1000\u20136. https:\/\/doi.org\/10.1210\/endo-112-3-1000.","journal-title":"Endocrinology."},{"issue":"1","key":"5556_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/jbmr.5650070110","volume":"7","author":"JM Hock","year":"1992","unstructured":"Hock JM, Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res. 1992;7(1):65\u201372. https:\/\/doi.org\/10.1002\/jbmr.5650070110.","journal-title":"J Bone Miner Res."},{"issue":"2","key":"5556_CR15","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1210\/endo-110-2-506","volume":"110","author":"CS Tam","year":"1982","unstructured":"Tam CS, Heersche JN, Murray TM, Parsons JA. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology. 1982;110(2):506\u201312. https:\/\/doi.org\/10.1210\/endo-110-2-506.","journal-title":"Endocrinology."},{"issue":"3","key":"5556_CR16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1677\/joe.1.06270","volume":"186","author":"A Iida-Klein","year":"2005","unstructured":"Iida-Klein A, Lu SS, Kapadia R, Burkhart M, Moreno A, Dempster DW, et al. Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL\/J6 mice. J Endocrinol. 2005;186(3):549\u201357. https:\/\/doi.org\/10.1677\/joe.1.06270.","journal-title":"J Endocrinol."},{"issue":"2","key":"5556_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.tem.2004.01.006","volume":"15","author":"L Qin","year":"2004","unstructured":"Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab. 2004;15(2):60\u20135. https:\/\/doi.org\/10.1016\/j.tem.2004.01.006.","journal-title":"Trends Endocrinol Metab."},{"issue":"9077","key":"5556_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","volume":"350","author":"R Lindsay","year":"1997","unstructured":"Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350(9077):550\u20135. https:\/\/doi.org\/10.1016\/S0140-6736(97)02342-8.","journal-title":"Lancet."},{"issue":"9","key":"5556_CR19","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1210\/jcem.85.9.6818","volume":"85","author":"ES Kurland","year":"2000","unstructured":"Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000;85(9):3069\u201376. https:\/\/doi.org\/10.1210\/jcem.85.9.6818.","journal-title":"J Clin Endocrinol Metab."},{"issue":"19","key":"5556_CR20","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434\u201341. https:\/\/doi.org\/10.1056\/NEJM200105103441904.","journal-title":"N Engl J Med."},{"issue":"1","key":"5556_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18(1):9\u201317. https:\/\/doi.org\/10.1359\/jbmr.2003.18.1.9.","journal-title":"J Bone Miner Res."},{"issue":"3","key":"5556_CR22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1359\/jbmr.2003.18.3.539","volume":"18","author":"JR Zanchetta","year":"2003","unstructured":"Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003;18(3):539\u201343. https:\/\/doi.org\/10.1359\/jbmr.2003.18.3.539.","journal-title":"J Bone Miner Res."},{"issue":"1","key":"5556_CR23","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.bone.2012.10.006","volume":"52","author":"CY Chiang","year":"2013","unstructured":"Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone. 2013;52(1):360\u20135. https:\/\/doi.org\/10.1016\/j.bone.2012.10.006.","journal-title":"Bone."},{"key":"5556_CR24","unstructured":"European Medicines Agency. Terrosa summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/terrosa-epar-product-information_en.pdf. Accessed 15 Apr 2020."},{"issue":"12","key":"5556_CR25","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1002\/jbmr.1768","volume":"27","author":"EB Andrews","year":"2012","unstructured":"Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7\u2009years. J Bone Miner Res. 2012;27(12):2429\u201337. https:\/\/doi.org\/10.1002\/jbmr.1768.","journal-title":"J Bone Miner Res."},{"issue":"10","key":"5556_CR26","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1007\/s00198-018-4604-8","volume":"29","author":"A Gilsenan","year":"2018","unstructured":"Gilsenan A, Harding A, Kellier-Steele N, Harris D, Midkiff K, Andrews E. The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8\u2009years. Osteoporos Int. 2018;29(10):2335\u201343. https:\/\/doi.org\/10.1007\/s00198-018-4604-8.","journal-title":"Osteoporos Int."},{"issue":"2","key":"5556_CR27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1359\/jbmr.090731","volume":"25","author":"P Aspenberg","year":"2010","unstructured":"Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):404\u201314. https:\/\/doi.org\/10.1359\/jbmr.090731.","journal-title":"J Bone Miner Res."},{"issue":"17","key":"5556_CR28","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2106\/JBJS.J.01379","volume":"93","author":"P Peichl","year":"2011","unstructured":"Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93(17):1583\u20137. https:\/\/doi.org\/10.2106\/JBJS.J.01379.","journal-title":"J Bone Joint Surg Am."},{"issue":"1","key":"5556_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/17453674.2015.1073050","volume":"87","author":"T Johansson","year":"2016","unstructured":"Johansson T. PTH 1-34 (teriparatide) may not improve healing in proximal humerus fractures. A randomized, controlled study of 40 patients. Acta Orthop. 2016;87(1):79\u201382. https:\/\/doi.org\/10.3109\/17453674.2015.1073050.","journal-title":"Acta Orthop."},{"issue":"5","key":"5556_CR30","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s11999-015-4669-z","volume":"474","author":"M Bhandari","year":"2016","unstructured":"Bhandari M, Jin L, See K, Burge R, Gilchrist N, Witvrouw R, et al. Does teriparatide improve femoral neck fracture healing: results from a randomized placebo-controlled trial. Clin Orthop Relat Res. 2016;474(5):1234\u201344. https:\/\/doi.org\/10.1007\/s11999-015-4669-z.","journal-title":"Clin Orthop Relat Res."},{"issue":"15","key":"5556_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018964","volume":"99","author":"G Fan","year":"2020","unstructured":"Fan G, Zhao Q, Lu P, Chen H, Tan W, Guo W, et al. Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis. Medicine (Baltimore). 2020;99(15):e18964. https:\/\/doi.org\/10.1097\/MD.0000000000018964.","journal-title":"Medicine (Baltimore)."},{"issue":"5","key":"5556_CR32","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/jbmr.3067","volume":"32","author":"J Malouf-Sierra","year":"2017","unstructured":"Malouf-Sierra J, Tarantino U, Garcia-Hernandez PA, Corradini C, Overgaard S, Stepan JJ, et al. Effect of teriparatide or risedronate in elderly patients with a recent pertrochanteric hip fracture: final results of a 78-week randomized clinical trial. J Bone Miner Res. 2017;32(5):1040\u201351. https:\/\/doi.org\/10.1002\/jbmr.3067.","journal-title":"J Bone Miner Res."},{"key":"5556_CR33","doi-asserted-by":"publisher","first-page":"100217","DOI":"10.1016\/j.bonr.2019.100217","volume":"11","author":"K Shigenobu","year":"2019","unstructured":"Shigenobu K, Hashimoto T, Kanayama M, Ohha H, Yamane S. The efficacy of osteoporotic treatment in patients with new spinal vertebral compression fracture pain, ADL, QOL, bone metabolism and fracture-healing - in comparison with weekly teriparatide with bisphosphonate. Bone Rep. 2019;11:100217. https:\/\/doi.org\/10.1016\/j.bonr.2019.100217.","journal-title":"Bone Rep."},{"issue":"3","key":"5556_CR34","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1210\/jc.2004-0826","volume":"90","author":"JC Gallagher","year":"2005","unstructured":"Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab. 2005;90(3):1583\u20137. https:\/\/doi.org\/10.1210\/jc.2004-0826.","journal-title":"J Clin Endocrinol Metab."},{"key":"5556_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jcte.2016.05.004","volume":"5","author":"EA Almirol","year":"2016","unstructured":"Almirol EA, Chi LY, Khurana B, Hurwitz S, Bluman EM, Chiodo C, et al. Short-term effects of teriparatide versus placebo on bone biomarkers, structure, and fracture healing in women with lower-extremity stress fractures: a pilot study. J Clin Transl Endocrinol. 2016;5:7\u201314. https:\/\/doi.org\/10.1016\/j.jcte.2016.05.004.","journal-title":"J Clin Transl Endocrinol."},{"issue":"2","key":"5556_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2217\/17455057.3.2.243","volume":"3","author":"JP Bilezikian","year":"2007","unstructured":"Bilezikian JP. Anabolic therapy for osteoporosis. Womens Health (Lond). 2007;3(2):243\u201353. https:\/\/doi.org\/10.2217\/17455057.3.2.243.","journal-title":"Womens Health (Lond)."},{"key":"5556_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4137\/CMED.S9663","volume":"5","author":"P Raghavan","year":"2012","unstructured":"Raghavan P, Christofides E. Role of teriparatide in accelerating metatarsal stress fracture healing: a case series and review of literature. Clin Med Insights Endocrinol Diabetes. 2012;5:39\u201345. https:\/\/doi.org\/10.4137\/CMED.S9663.","journal-title":"Clin Med Insights Endocrinol Diabetes."},{"key":"5556_CR38","unstructured":"Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, D.C.: National Academies Press; 2011. p. 345\u2013455."},{"issue":"4","key":"5556_CR39","doi-asserted-by":"publisher","first-page":"878","DOI":"10.2214\/AJR.11.6826","volume":"198","author":"R Kijowski","year":"2012","unstructured":"Kijowski R, Choi J, Shinki K, Del Rio AM, De Smet A. Validation of MRI classification system for tibial stress injuries. AJR Am J Roentgenol. 2012;198(4):878\u201384. https:\/\/doi.org\/10.2214\/AJR.11.6826.","journal-title":"AJR Am J Roentgenol."},{"issue":"4","key":"5556_CR40","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1177\/036354659502300418","volume":"23","author":"M Fredericson","year":"1995","unstructured":"Fredericson M, Bergman AG, Hoffman KL, Dillingham MS. Tibial stress reaction in runners. Correlation of clinical symptoms and scintigraphy with a new magnetic resonance imaging grading system. Am J Sports Med. 1995;23(4):472\u201381. https:\/\/doi.org\/10.1177\/036354659502300418.","journal-title":"Am J Sports Med."},{"issue":"3","key":"5556_CR41","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1148\/radiol.12102426","volume":"263","author":"BR Beck","year":"2012","unstructured":"Beck BR, Bergman AG, Miner M, Arendt EA, Klevansky AB, Matheson GO, et al. Tibial stress injury: relationship of radiographic, nuclear medicine bone scanning, MR imaging, and CT Severity grades to clinical severity and time to healing. Radiology. 2012;263(3):811\u20138. https:\/\/doi.org\/10.1148\/radiol.12102426.","journal-title":"Radiology."},{"issue":"9","key":"5556_CR42","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1111\/j.1365-2044.1976.tb11971.x","volume":"31","author":"SI Revill","year":"1976","unstructured":"Revill SI, Robinson JO, Rosen M, Hogg MI. The reliability of a linear analogue for evaluating pain. Anaesthesia. 1976;31(9):1191\u20138. https:\/\/doi.org\/10.1111\/j.1365-2044.1976.tb11971.x.","journal-title":"Anaesthesia."},{"issue":"1","key":"5556_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0304-3959(83)90088-X","volume":"16","author":"AM Carlsson","year":"1983","unstructured":"Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain. 1983;16(1):87\u2013101. https:\/\/doi.org\/10.1016\/0304-3959(83)90088-X.","journal-title":"Pain."},{"issue":"6","key":"5556_CR44","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383. https:\/\/doi.org\/10.1097\/00005650-199206000-00002.","journal-title":"Med Care."},{"issue":"1","key":"5556_CR45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/00005650-199401000-00004","volume":"32","author":"CA McHorney","year":"1994","unstructured":"McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32(1):40\u201366. https:\/\/doi.org\/10.1097\/00005650-199401000-00004.","journal-title":"Med Care."},{"key":"5556_CR46","first-page":"110","volume-title":"Bone health and osteoporosis: a report of the Surgeon General","author":"Office of the Surgeon General","year":"2004","unstructured":"Office of the Surgeon General. Determinants of bone health. In: Bone health and osteoporosis: a report of the Surgeon General. Rockville: Department of Health and Human Services; 2004. p. 110\u201356."},{"issue":"jan08 15","key":"5556_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346(jan08 15):e7586. https:\/\/doi.org\/10.1136\/bmj.e7586.","journal-title":"BMJ."},{"issue":"23","key":"5556_CR48","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/jama.2017.18556","volume":"318","author":"C Gamble","year":"2017","unstructured":"Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Dore C, et al. Guidelines for the content of statistical analysis plans in clinical trials. JAMA. 2017;318(23):2337\u201343. https:\/\/doi.org\/10.1001\/jama.2017.18556.","journal-title":"JAMA."},{"issue":"mar23 1","key":"5556_CR49","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340(mar23 1):c332. https:\/\/doi.org\/10.1136\/bmj.c332.","journal-title":"BMJ."},{"issue":"1","key":"5556_CR50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/0363546515574066","volume":"44","author":"AA Wright","year":"2016","unstructured":"Wright AA, Hegedus EJ, Lenchik L, Kuhn KJ, Santiago L, Smoliga JM. Diagnostic accuracy of various imaging modalities for suspected lower extremity stress fractures: a systematic review with evidence-based recommendations for clinical practice. Am J Sports Med. 2016;44(1):255\u201363. https:\/\/doi.org\/10.1177\/0363546515574066.","journal-title":"Am J Sports Med."},{"key":"5556_CR51","unstructured":"European Medicines Agency. Forsteo: procedural steps taken and scientific information after the authorisation. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/forsteo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf. Accessed 10 Aug 2020."},{"key":"5556_CR52","doi-asserted-by":"publisher","first-page":"1759720X1987799","DOI":"10.1177\/1759720X19877994","volume":"11","author":"S Minisola","year":"2019","unstructured":"Minisola S, Cipriani C, Grotta GD, Colangelo L, Occhiuto M, Biondi P, et al. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2019;11:1759720X19877994.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"5556_CR53","unstructured":"European Commission Directorate-General Environment Nuclear Safety and Civil Protection. Radiation protection 99: guidance on medical exposures in medical and biomedical research. 1998. https:\/\/ec.europa.eu\/energy\/sites\/ener\/files\/documents\/099_en.pdf. Accessed 16 Apr 2020."},{"issue":"4","key":"5556_CR54","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1172\/JCI133473","volume":"130","author":"JY Li","year":"2020","unstructured":"Li JY, Yu M, Pal S, Tyagi AM, Dar H, Adams J, et al. Parathyroid hormone-dependent bone formation requires butyrate production by intestinal microbiota. J Clin Invest. 2020;130(4):1767\u201381. https:\/\/doi.org\/10.1172\/JCI133473.","journal-title":"J Clin Invest."},{"key":"5556_CR55","doi-asserted-by":"crossref","unstructured":"HM Government. Managing clinical trials during Coronavirus (COVID-19). 2020. https:\/\/www.gov.uk\/guidance\/managing-clinical-trials-during-coronavirus-covid-19#managing-ongoing-and-halted-trials. Accessed 24 June 2020.","DOI":"10.1016\/j.conctc.2020.100637"},{"issue":"2","key":"5556_CR56","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bcp.13455","volume":"84","author":"D Tay","year":"2018","unstructured":"Tay D, Cremers S, Bilezikian JP. Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology. Br J Clin Pharmacol. 2018;84(2):252\u201367. https:\/\/doi.org\/10.1111\/bcp.13455.","journal-title":"Br J Clin Pharmacol."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05556-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05556-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05556-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T12:13:37Z","timestamp":1630325617000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05556-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5556"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05556-3","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"assertion":[{"value":"4 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by MODREC, reference 932\/MODREC\/18. Written, informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Consent for publication is not applicable. A model consent form is available upon request","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"WDF has received unrestricted research grants, sat on advisory boards, and given lectures on behalf of Eli Lilly, NPS Pharmaceuticals, Shire and Nycomed. JWM has received research grants and consultancy fees from GlaxoSmithKline and GE Healthcare. ATC, KGE, AC, MH, LS, EP, APT, AMS and JPG declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"580"}}